Abstract:Abstract Background Kidney renal clear cell carcinoma (KIRC), as a common case in renal cell carcinoma (RCC), has the risk of postoperative recurrence, thus its prognosis is poor and its prognostic markers are usually based on imaging methods, which have the problem of low specificity. In addition, cuproptosis, as a novel mode of cell death, has been used as a biomarker to predict disease in many cancers in recent years, which also provides an important basis for prognostic prediction in KIRC. For postoperative patients with KIRC, an important means of preventing disease recurrence is pharmacological treatment, and thus matching the appropriate drug to the specific patient's target is also particularly important. With the development of neural networks, their predictive performance in the field of medical big data has surpassed that of traditional methods, and this also applies to the field of prognosis prediction and drug‐target prediction. Objective The purpose of this study is to screen for cuproptosis genes related to the prognosis of KIRC and to establish a deep neural network (DNN) model for patient risk prediction, while also developing a personalized nomogram model for predicting patient survival. In addition, sensitivity drugs for KIRC were screened, and a graph neural network (GNN) model was established to predict the targets of the drugs, in order to discover potential drug action sites and provide new treatment ideas for KIRC. Methods We used the Cancer Genome Atlas (TCGA) database, International Cancer Genome Consortium (ICGC) database, and DrugBank database for our study. Differentially expressed genes (DEGs) were screened using TCGA data, and then a DNN‐based risk prediction model was built and validated using ICGC data. Subsequently, the differences between high‐ and low‐risk groups were analyzed and KIRC‐sensitive drugs were screened, and finally a GNN model was trained using DrugBank data to predict the relevant targets of these drugs. Results A prognostic model was built by screening 10 significantly different cuproptosis‐related genes, the model had an AUC of 0.739 on the training set (TCGA data) and an AUC of 0.707 on the validation set (ICGC data), which demonstrated a good predictive performance. Based on the prognostic model in this paper, patients were also classified into high‐ and low‐risk groups, and functional analyses were performed. In addition, 251 drugs were screened for sensitivity, and four drugs were ultimately found to have high sensitivity, with 5‐Fluorouracil having the best inhibitory effect, and subsequently their corresponding targets were also predicted by GraphSAGE, with the most prominent targets including Cytochrome P450 2D6, UDP‐glucuronosyltransferase 1A, and Proto‐oncogene tyrosine‐protein kinase receptor Ret. Notably, the average accuracy of GraphSAGE was 0.817 ± 0.013, which was higher than that of GAT and GTN. Conclusion Our KIRC risk prediction model, constructed using 10 cuproptosis‐related genes, had good independent prognostic ability. In addition, we screened four highly sensitive drugs and predicted relevant targets for these four drugs that might treat KIRC. Finally, literature research revealed that four drug‐target interactions have been demonstrated in previous studies and the remaining targets are potential sites of drug action for future research.

The value of erlotinib related target molecules in kidney renal cell carcinoma via bioinformatics analysis

Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma

The Role of ERBB Signaling Pathway-Related Genes in Kidney Renal Clear Cell Carcinoma and Establishing a Prognostic Risk Assessment Model for Patients

Prognostic model for clear-cell renal cell carcinoma based on natural killer cell-related genes.

The Promising Novel Biomarkers and Candidate Small Molecule Drugs in Kidney Renal Clear Cell Carcinoma: Evidence from Bioinformatics Analysis of High‐throughput Data

Comprehensive analysis of resistance mechanisms to EGFR–TKIs and establishment and validation of prognostic model

A novel endothelial-related prognostic index by integrating single-cell and bulk RNA sequencing data for patients with kidney renal clear cell carcinoma

Identification and validation of differentially expressed genes for targeted therapy in NSCLC using integrated bioinformatics analysis

Integrative bioinformatics analysis of a prognostic index and immunotherapeutic targets in renal cell carcinoma

Identified Gefitinib Metabolism-Related lncRNAs can be Applied to Predict Prognosis, Tumor Microenvironment, and Drug Sensitivity in Non-Small Cell Lung Cancer

Identification of small molecule drugs and development of a novel autophagy‐related prognostic signature for kidney renal clear cell carcinoma

A Novel KIF4A-Related Model for Predicting Immunotherapy Response and Prognosis in Kidney Renal Clear Cell Carcinoma

Identification of Key Biomarkers and Potential Molecular Mechanisms in Renal Cell Carcinoma by Bioinformatics Analysis

Integrated Bioinformatics Analysis to Identify Key Genes Related to the Prognosis of Esophageal Squamous Cell Carcinoma

Identification of Significant Genes with Prognostic Influence in Clear Cell Renal Cell Carcinoma Via Bioinformatics Analysis.

Identification of the Prognosis Value and Potential Mechanism of Immune Checkpoints in Renal Clear Cell Carcinoma Microenvironment

Gefitinib metabolism-related lncRNAs for the prediction of prognosis, tumor microenvironment and drug sensitivity in lung adenocarcinoma

Identification and Validation of a Prognostic Signature Based on Fibroblast Immune-related Genes to Predict the Prognosis and Therapeutic Response of renal clear cell carcinoma by Integrated Analysis of Single-Cell and Bulk RNA Sequencing Data

Cuproptosis Gene‐related, Neural Network‐based Prognosis Prediction and Drug‐target Prediction for KIRC

ETNK2 Low-Expression Predicts Poor Prognosis in Renal Cell Carcinoma with Immunosuppressive Tumor Microenvironment

Bioinformatics analysis and verification of gene targets for renal clear cell carcinoma